Related Experiment Video
Updated: Apr 18, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
The cost of biologics for psoriasis is increasing
Judy Cheng1, Steven R Feldman2
1Center for Dermatology Research, Departments of Dermatology, Winston-Salem, NC, USA.
Background:
Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with "traditional" agents. Cost must be considered when evaluating management options for psoriasis.
Objective:
To estimate the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.
Methods:
The cost of annual treatment paradigms for etanercept, adalimumab, and ustekinumab was estimated using the average wholesale price. Trends were assessed by calculating the percentage change in annual cost compared with the previous year. A sales-based cost of drugs was estimated using gross US sales of each drug and an estimate of the total number of patients treated based on prescription data.
Results:
The cost of one year of induction and maintenance treatment was highest for ustekinumab ($53,909), followed by etanercept ($46,395), and adalimumab ($39,041). The sales-based cost of drugs was greatest for ustekinumab ($25,012), then adalimumab ($6,786) and etanercept ($6,629). Sales-based cost increased at an average of 20% per year.
Conclusion:
The cost of biologic treatments for psoriasis has been increasing. Cost considerations in the management of psoriasis are likely to increase given the limited healthcare resources that are available.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Bioequivalence: Overview
EPS and iPS Cells in Disease Research

